High-dose ibuprofen linked to small increased CV risk, EMA committee confirms
This article was originally published in Scrip
A European Medicines Agency committee has confirmed that there is a small increase in the risk of cardiovascular problems such as heart attacks and stroke in patients taking high doses – 2,400mg or more – of ibuprofen, and has recommended that the labelling of products containing the anti-inflammatory drug should be updated to reflect this risk.
You may also be interested in...
Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.
Neurodegenerative and cardiovascular diseases, along with cancer and early feasibility studies, are among the topics to be addressed by consortia interested in taking part in the EU’s latest research partnership.
A new industry report has painted a sobering picture of the UK life sciences sector, which is facing challenges on a number of fronts including clinical research, market access and manufacturing. On the bright side, the report says that implementing the measures in the government’s Life Sciences Vision could make the UK a “world-leading” hub for drug discovery and development.